Trial reportBritish journal of cancer2001
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
Trial report in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Effect of administering recombinant erythropoietin to women with postpartum anemia: a meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2004Pooled it
- Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.British journal of cancer · 2002Trial
- Erythropoietin as a Neuroprotective Drug for Newborn Infants: Ten Years after the First Use.Antioxidants (Basel, Switzerland) · 2022Review
- Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies.Trends in molecular medicine · 2021Review
- Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future Research.International journal of molecular sciences · 2020Review
- Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Review
- Improving Immunotherapy Through Glycodesign.Frontiers in immunology · 2018Review
- Scientific literature on monosialoganglioside in the Science Citation Index-Expanded: A bibliometric analysis of articles from 1942 to 2011 by each decade.Neural regeneration research · 2012Article
- Pretreatment with darbepoetin attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity.The Korean journal of internal medicine · 2009Article
- Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.Therapeutics and clinical risk management · 2007Article
- Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysis.Clinical drug investigation · 2005Article
- Review
- Clinical and economic impact of epoetins in cancer care.PharmacoEconomics · 2004Review
- Recombinant erythropoietin in clinical practice.Postgraduate medical journal · 2003Review
- Review
- Darbepoetin alfa (Aranesp).Proceedings (Baylor University. Medical Center) · 2002Article
- Review
- Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.British journal of cancer · 2001Review
- Introduction. Improving the standard of care in the management of cancer-related anaemia: focus on darbepoetin alfa, a novel erythropoiesis-stimulating protein.British journal of cancer · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaemia is a common haematologic disorder in patients with cancer and has a multifactorial aetiology, including the effects of the malignancy itself and residual effects from previous therapy. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa), a protein with additional sialic acid compared with erythropoietin (EPO), stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO) but it is biochemically distinct. NESP, with its approximately 3-fold greater serum half-life, can maintain haemoglobin levels as effectively as rHuEPO in anaemic patients with chronic renal failure and do so with less frequent dosing. We investigated the ability of NESP to safely increase haemoglobin levels of anaemic patients with non-myeloid malignancies not receiving chemotherapy. NESP was administered under the supervision of a physician at doses of 0.5, 1.0, 2.25 or 4.5 mcg kg(-1)wk(-1)for a maximum of 12 weeks. This report includes 89 patients completing the study by November 2000. NESP was well tolerated, with no reported dose-limiting toxicities or treatment-related severe adverse events. Increasing doses of NESP corresponded with increased efficacy. The percentage (95% confidence interval) of patients responding ranged from 61% (42%, 77%) in the 1.0 mcg kg(-1)wk(-1)group to 83% (65%, 94%) in the 4.5 mcg kg(-1)wk(-1)group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.